Replies to post #557432 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

CRL will be vastly more expensive over time and IP for all aspects of production are much better at the company’s own factory. CRL is not likely to lower their prices and come work at Sawston and there would likely be no reason for NWBO to contemplate a midstream change for no reason. I believe the Advent contract otherwise mirrors the CRL previous contract in all respects other than it is not at the CRL factory. But I don’t think it’s best to do the development work for Flaskworks at another company’s facility. This will be key technology for extending patents for decades.

[skitahoe]

Doc it's sad that our FDA can't be more like the British and agree to a price for sale in compassionate use, perhaps for commercial use as well. It should be clear that the cost of commercial production should be lower than the cost of making trial product, so if they'd agree to a commercial price up front charging the same for compassionate use certainly wouldn't have nearly a great a profit, though they might make a small profit.

Our FDA wants companies to provide them the data on what the costs are in order to charge for compassionate care products, the results are that companies aren't willing to provide that information so they either provide the product for free, or don't supply it at all. Most choose not to supply it at all. In short, it's simply a nice sounding program here, but it's not working.

I think you're right about what the price will be in the U.K. post approval, essentially the same as under compassionate use, but now it will be paid for through their medical plans. I cannot say if patients pay some percentage, or not, and the same would apply here depending on your insurance plan.

Gary